FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022200814> ?p ?o ?g. }

• W2022200814 abstract "Haloperidol (Haldol) is a member of the butyrophenone class of neuroleptic drugs used in the treatment of patients with psychotic disorders (for example, schizophrenia). It is also used to control the tics and verbal utterances associated with Gilles de la Tourette's syndrome and to manage intensely hyperexcitable children whose condition does not respond to other treatment modalities. Often, its use is associated with severe toxic side effects, the most serious of which are tardive dyskinesia (which can be irreversible), extrapyramidal reactions with Parkinson-like symptoms, and neuroleptic malignant syndrome. Less serious side effects can include hypotension, anticholinergic effects (blurred vision, dry mouth, constipation, and urinary retention), and sedation, but these effects occur less frequently than with phenothiazine therapy. Although the mechanism of action of haloperidol has not been completely elucidated, its pharmacodynamic activity seems to be related, in part, to its ability to function as a dopamine-receptor antagonist in the central nervous system. Specifically, its effects are thought to be related to the blockage of dopamine receptors in the basal ganglia and limbic regions of the brain.1 Pharmacokinetics.—Substantial interindividual variability is observed in the systemic disposition of haloperidol. Haloperidol is well absorbed from the gastrointestinal tract, but first-pass hepatic metabolism decreases oral bioavailability to 40 to 75%. Serum concentrations peak in 0.5 to 4 hours after an oral dose. The apparent volume of distribution of 11 to 25 L/kg is consistent with the high degree of lipophilicity of the drug and indicates extensive extravascular localization at steady state. Haloperidol circulates in blood predominantly (90 to 94%) bound to plasma proteins. Renal excretion of the parent drug is negligible, and clearance occurs almost exclusively by hepatic metabolism. Unlike the phenothiazines that produce an array of active metabolites, only one active metabolite of haloperidol has been identified to date. This metabolite, reduced haloperidol, is produced by hydroxylation of haloperidol and retains only approximately 10% of the pharmacologie activity of the parent drug. In patients with normal liver function," @default.
• W2022200814 created "2016-06-24" @default.
• W2022200814 creator A5082276345 @default.
• W2022200814 date "1994-02-01" @default.
• W2022200814 modified "2023-09-23" @default.
• W2022200814 title "Monitoring of Serum Haloperidol" @default.
• W2022200814 cites W115808356 @default.
• W2022200814 cites W1984402704 @default.
• W2022200814 cites W1985279219 @default.
• W2022200814 cites W2015116703 @default.
• W2022200814 cites W2027127607 @default.
• W2022200814 cites W2041214037 @default.
• W2022200814 cites W2042470481 @default.
• W2022200814 cites W2123242720 @default.
• W2022200814 cites W2410589825 @default.
• W2022200814 cites W2462326694 @default.
• W2022200814 doi "https://doi.org/10.1016/s0025-6196(12)61048-9" @default.
• W2022200814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8309272" @default.
• W2022200814 hasPublicationYear "1994" @default.
• W2022200814 type Work @default.
• W2022200814 sameAs 2022200814 @default.
• W2022200814 citedByCount "7" @default.
• W2022200814 crossrefType "journal-article" @default.
• W2022200814 hasAuthorship W2022200814A5082276345 @default.
• W2022200814 hasConcept C118552586 @default.
• W2022200814 hasConcept C126322002 @default.
• W2022200814 hasConcept C137183658 @default.
• W2022200814 hasConcept C2776412080 @default.
• W2022200814 hasConcept C2778689640 @default.
• W2022200814 hasConcept C2779158372 @default.
• W2022200814 hasConcept C2780494398 @default.
• W2022200814 hasConcept C2780616385 @default.
• W2022200814 hasConcept C2780948584 @default.
• W2022200814 hasConcept C42219234 @default.
• W2022200814 hasConcept C513476851 @default.
• W2022200814 hasConcept C71924100 @default.
• W2022200814 hasConcept C98274493 @default.
• W2022200814 hasConceptScore W2022200814C118552586 @default.
• W2022200814 hasConceptScore W2022200814C126322002 @default.
• W2022200814 hasConceptScore W2022200814C137183658 @default.
• W2022200814 hasConceptScore W2022200814C2776412080 @default.
• W2022200814 hasConceptScore W2022200814C2778689640 @default.
• W2022200814 hasConceptScore W2022200814C2779158372 @default.
• W2022200814 hasConceptScore W2022200814C2780494398 @default.
• W2022200814 hasConceptScore W2022200814C2780616385 @default.
• W2022200814 hasConceptScore W2022200814C2780948584 @default.
• W2022200814 hasConceptScore W2022200814C42219234 @default.
• W2022200814 hasConceptScore W2022200814C513476851 @default.
• W2022200814 hasConceptScore W2022200814C71924100 @default.
• W2022200814 hasConceptScore W2022200814C98274493 @default.
• W2022200814 hasLocation W20222008141 @default.
• W2022200814 hasLocation W20222008142 @default.
• W2022200814 hasOpenAccess W2022200814 @default.
• W2022200814 hasPrimaryLocation W20222008141 @default.
• W2022200814 hasRelatedWork W160185297 @default.
• W2022200814 hasRelatedWork W2010174773 @default.
• W2022200814 hasRelatedWork W2033868099 @default.
• W2022200814 hasRelatedWork W2061785172 @default.
• W2022200814 hasRelatedWork W2085929015 @default.
• W2022200814 hasRelatedWork W2182100643 @default.
• W2022200814 hasRelatedWork W2418166582 @default.
• W2022200814 hasRelatedWork W2465896322 @default.
• W2022200814 hasRelatedWork W2681878784 @default.
• W2022200814 hasRelatedWork W3189717997 @default.
• W2022200814 isParatext "false" @default.
• W2022200814 isRetracted "false" @default.
• W2022200814 magId "2022200814" @default.
• W2022200814 workType "article" @default.